Syngene is at the Heart of Biologics, offering integrated services across the drug discovery, development and manufacturing continuum. We are committed to incrementally adding new layers of expertise to drive continued innovation. Solving our partners’ complex research and manufacturing problems, has been the hallmark of our success, and sustainable long-term relationships.
We work with diverse Biological entities like Monoclonal Antibodies, Bispecifics, Antibody Fragments, Recombinant Proteins, Glycoproteins, Pegylated Proteins, Subunit Protein Vaccines, mRNA, microbial (E. coli and Pichia), microbiome Live Biotherapeutic Product (LBP) and Multimeric Protein Complexes.
We are a fully integrated custom biomanufacturer. Our Large molecules manufacturing facility caters to multi-product production campaigns simultaneously, based on single-use technology platform.
Syngene reported a 19% growth in revenue from operations for the entire year of FY22. Watch this video as our CEO and MD, Jonathan Hunt, speaks about Syngene’s performance, the outlook for FY 23, Syngene’s contribution in the fight against the pandemic, focus areas for the coming year, and more.